Drugs / OLX-07010
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | — | “an investigational new drug (IND) application with the U.S. Food and Drug Administration, which was filed in mid-2022” oligomerix.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05696483 | Jan 2023 → Jun 2026 overdue | Alzheimer disease | Oligomerix, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-02-02 | Oligomerix, Inc | Results Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010 oligomerix.com ↗
Oligomerix, Inc., a clinical-stage biotechnology company pioneering the development of a platform of tau self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerat ive disorders, announced today the publication of preclinical data demonstrating that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). |
| 2022-11-30 | Oligomerix, Inc | Results Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings oligomerix.com ↗
At the meetings, the company presented data from IND-enabling studies demonstrating the safety and pharmacokinetic profile of OLX-07010 in in vitro and in vivo preclinical studies. |
| 2021-11-09 | Oligomerix, Inc | Results Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting oligomerix.com ↗
Statistically significant results showed that treatment prevented further accumulation of tau aggregates and overall levels of tau in the mice over 5 months of treatment administered in the feed compared to control animals. |
| 2021-07-30 | Oligomerix, Inc | Results Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies oligomerix.com ↗
The data from our preclinical studies continue to support our differentiated approach targeting tau self-association, an upstream mechanism at the beginning of the tau aggregation cascade, for reducing tau pathology. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OLX-07010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05696483 ↗ |
| Action | Inhibit | “tau self-association inhibitor” NCT05696483 ↗ |